
MindMed (NASDAQ:MNMD), a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog.
Shares from the company peaked at $1.30 and closed the Tuesday trading session at $1.17, marking a 25% increase from the previous day.